Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemoradiotherapy in High-Risk LANPC
NCT06749899Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started May 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06749899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749899.